FEATURED CONTENT

• Gene, Cell, & RNA Therapy Landscape: Q1 2023 Data Report

  Get insight from the 2023 first quarter gene, cell, and RNA therapies report composed by Citeline, in conjunction with the American Society of Gene & Cell Therapy (ASGCT).

• Reimagining The Future: One Chapter At A Time

  Get a glimpse of how the pharmaceutical industry has emerged from the tumultuous episode of the COVID-19 pandemic, stronger and emboldened.

• New Active Substances Launched In 2022: Pharma R&D Annual Review 2023 Supplement

  In a sequel to the Pharma R&D Report, the author explores drugs that brought something genuinely new to the world of medicine in 2022 — new active substances (NASs) with some kind of novelty — that just might change the story of patients’ lives.

• Cross-Border M&A: 10 Key Trends To Watch In 2023

  Many observers believe deal volume will remain buoyant throughout 2023. The need for access to cash is expected to continue to drive M&A decision-making. Heightened regulatory scrutiny, supply chain weakness, and consolidation are a few of the trends to watch for the remainder of the year.

• The State Of Global Clinical Trial Disclosure

  See what industry organizations are saying about trial transparency, regulations by region, what penalties are on the books, and whether they are enforced.

• Pharma R&D Annual Review 2023

  Although COVID-19 has not quite finished its final act, it appears the industry is emerging from this tumultuous episode stronger and emboldened. Find out if the 2023 pipeline was a page-turner in this literary-themed Pharmaprojects’ 2023 review of trends in pharmaceutical R&D.

• 'Pivotal Time For CROs': ICON CEO Cutler On Changing APAC Trial Trends

  The CEO of one of the global top five CROs recently pointed out an opportunity in decentralized trials that might be a “game changer” in the pharma industry over the next five years. He also refers to the need to accept new technologies by both clinical trial sites and regulators.

• Cardio Conversations: PFA, Electrophysiology, And What It Takes To Be A Physician Inventor

  Co-Founder of Farapulse and Field Medical Steven Mickelsen and Medtech Insight Editor Reed Miller discuss pulsed field ablation, an emerging technology that is changing electrophysiology.

• Unlocking The Potential Of Decentralized Clinical Trials

  Explore the current DCT landscape and its evolution, as well as the key advantages of incorporating decentralized attributes and how barriers to their inclusion can be overcome.

• Cardio Conversations: PFA Electrophysiology And What It Takes To Be a Physician Inventor

  Hear from Steven Mickelsen, a pioneer in pulsed field ablation (PFA), as he delves into how PFA is set to change the electrophysiology market as well as his experiences as a physician-entrepreneur. 

• US FDA May Become More Insistent On Accelerated Approval Confirmatory Trials Timing

  Learn how review divisions may take a tougher line with sponsors on the design and timing of studies to verify clinical benefit.

• The Stories And Statistics Behind Breast Cancer: Part Two

  In part two of a survivor series, several individuals who beat breast cancer, and their loved ones, discuss the challenges and treatments they underwent while fighting the disease.

• The Stories And Statistics Behind Breast Cancer: Part One

  As told by survivors of breast cancer and their loved ones, learn about the treatments, and challenges they all faced while battling the disease.

• Gene, Cell, & RNA Therapy Landscape: Q4 2022 Data Report

  Get insight from the 2022 fourth quarter gene, cell, and RNA therapies report composed by Citeline, in conjunction with the American Society of Gene & Cell Therapy (ASGCT).

• In The CROsshairs: CROs And Clinical Trial Disclosure Compliance

  Read about why CROs must fully understand how the nuances of regulatory compliance, particularly clinical trial disclosure, fit into and impact the entire lifespan of a study.

• 7 Industry Leaders Weigh In On Patient Engagement & Recruitment

  Gain insight from leaders representing unique facets of the clinical trial ecosystem. See what they have to say about stakeholder relationships, diversity in clinical trials, smoothing the path to treatment options, the importance of transparency, and more.

• Trial Rescue: Site Selection And Prioritization

  A large pharmaceutical company was looking to validate its list of 100+ US sites for a chronic auto-immune disease study. Leveraging medical claims data, a site-level analysis was conducted to identify relevant patients meeting the trial’s I/E criteria.

• Operationalizing Disclosure Intelligence For Go-To-Market Success

  Regulatory intelligence goes beyond ensuring compliance. By monitoring and understanding these integral disclosure obligations, sponsors can position clinical trials for seamless completion from the start, and position themselves as industry leaders.

• Navigating The Growing Complexities Of Global Clinical Trial Disclosure In 2022 And Beyond

  New government disclosure regulations are emerging. Regulations from public health organizations around the globe have increased administrative compliance tasks and driven up the consequences of noncompliance. 

• The State Of Innovation In Europe

  Discover the current state of innovation in Europe, from pipeline constitution to emerging drug modalities, R&D alliances to financing trends.